title: Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone.
abstract: Vesnarinone is an orally administered inotropic agent that is metabolized in vitro by the cytochrome P450 (CYP) isozymes CYP3A4 and CYP2E1. The purpose of this study was to assess the contribution of CYP2E1 activity to the disposition of vesnarinone in humans by characterizing the pharmacokinetics before and after disulfiram-mediated CYP2E1 inhibition. The pharmacokinetics of vesnarinone 60 mg were determined in normal healthy volunteers (N = 7) before and after daily disulfiram administration (250 mg). Chlorzoxazone 250 mg was also administered before, during, and after disulfiram administration to serve as a positive control for CYP2E1 inhibition. Disulfiram treatment decreased 6-hydroxychlorzoxazone formation clearance by nearly 95% but effected only a modest decrease in vesnarinone apparent oral clearance (5.7 +/- 1.0 vs. 5.0 +/- 0.5 ml/min; p = 0.022). In contrast to the modest effect on the parent drug, disulfiram treatment substantially increased plasma concentrations of the primary metabolite OPC-18692. The Cmax of OPC-18692 was increased approximately 7-fold, and the area under the plasma concentration-time curve was increased 18-fold (2.9 +/- 0.9 vs. 53.7 +/- 33.2 micrograms.h/ml; p = 0.006). The results indicate that CYP2E1 inhibition has only a modest, clinically insignificant effect on vesnarinone disposition but markedly increases plasma concentrations of the OPC-18692 metabolite. The pharmacological properties of this metabolite have not been fully defined; thus, the clinical importance of this observation depends on whether this metabolite contributes to any of the toxicity associated with vesnarinone administration.
authors.affiliation: Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, PA 15261, USA.
authors.forename: R F
authors.initials: RF
authors.lastname: Frye
authors.forename: B
authors.initials: B
authors.lastname: Tammara
authors.forename: T D
authors.initials: TD
authors.lastname: Cowart
authors.forename: S L
authors.initials: SL
authors.lastname: Bramer
mesh_terms: D000328:Adult; D002316:Cardiotonic Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D002753:Chlorzoxazone / Q000493:pharmacokinetics / Q000494:pharmacology; D065691:Cytochrome P-450 CYP2E1 Inhibitors; D004221:Disulfiram / Q000494:pharmacology*; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D008297:Male; D011719:Pyrazines; D011804:Quinolines / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D013997:Time Factors
chemical_list: D002316:Cardiotonic Agents; D065691:Cytochrome P-450 CYP2E1 Inhibitors; D004791:Enzyme Inhibitors; D011719:Pyrazines; D011804:Quinolines; C041667:vesnarinone; D002753:Chlorzoxazone; D004221:Disulfiram